US20220211679A1 - Alpha 7 nicotinic acetylcholine receptor agonists - Google Patents
Alpha 7 nicotinic acetylcholine receptor agonists Download PDFInfo
- Publication number
- US20220211679A1 US20220211679A1 US17/700,469 US202217700469A US2022211679A1 US 20220211679 A1 US20220211679 A1 US 20220211679A1 US 202217700469 A US202217700469 A US 202217700469A US 2022211679 A1 US2022211679 A1 US 2022211679A1
- Authority
- US
- United States
- Prior art keywords
- azabicyclo
- oct
- methyl
- yloxy
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 title claims abstract description 8
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 title claims abstract description 8
- 229940044601 receptor agonist Drugs 0.000 title claims abstract 3
- 239000000018 receptor agonist Substances 0.000 title claims abstract 3
- 206010016256 fatigue Diseases 0.000 claims abstract description 106
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 230000002265 prevention Effects 0.000 claims abstract description 20
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 9
- 206010041349 Somnolence Diseases 0.000 claims abstract description 7
- 230000000422 nocturnal effect Effects 0.000 claims abstract description 5
- 208000001573 Cataplexy Diseases 0.000 claims abstract description 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims abstract 3
- 239000000556 agonist Substances 0.000 claims description 87
- 150000001875 compounds Chemical class 0.000 claims description 75
- 150000003839 salts Chemical group 0.000 claims description 31
- 201000006417 multiple sclerosis Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 26
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 26
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 23
- 239000012458 free base Substances 0.000 claims description 23
- 230000007958 sleep Effects 0.000 claims description 18
- -1 N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide Chemical compound 0.000 claims description 15
- NPDLTEZXGWRMLQ-IBGZPJMESA-N (3r)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical group C1=CC(C)=CC=C1C(N=C1)=CC=C1O[C@@H]1C(CC2)CCN2C1 NPDLTEZXGWRMLQ-IBGZPJMESA-N 0.000 claims description 10
- QZDCYUCETTWCMO-UHFFFAOYSA-N abt126 Chemical compound C1C(C2)CC3CN2CC1C3OC(S1)=NN=C1C1=CC=CC=C1 QZDCYUCETTWCMO-UHFFFAOYSA-N 0.000 claims description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 8
- 208000010340 Sleep Deprivation Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N DMXB-A Chemical group COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- OCKIPDMKGPYYJS-ZDUSSCGKSA-N (3r)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1N(CC2)CCC2[C@]21OC1=NC=CC=C1C2 OCKIPDMKGPYYJS-ZDUSSCGKSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 claims description 6
- ZFLIWLTZPYHUBM-UHFFFAOYSA-N n-methyl-1-(5-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine]-5'-ylthiophen-2-yl)methanamine Chemical compound S1C(CNC)=CC=C1C1=CN=C(OC2(C3)C4CCN(CC4)C2)C3=C1 ZFLIWLTZPYHUBM-UHFFFAOYSA-N 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- FAXKPTBQVYYOOM-UHFFFAOYSA-N 4-[5-(1H-indol-5-yl)pyrimidin-2-yl]oxy-1-azatricyclo[3.3.1.13,7]decane Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)OC2C3CN4CC2CC(C4)C3)=C1 FAXKPTBQVYYOOM-UHFFFAOYSA-N 0.000 claims description 5
- MFXIUJQRWWZJHY-UHFFFAOYSA-N 4-[6-(1H-indol-5-yl)pyridazin-3-yl]oxy-1-azatricyclo[3.3.1.13,7]decane Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)OC2C3CN4CC2CC(C4)C3)=C1 MFXIUJQRWWZJHY-UHFFFAOYSA-N 0.000 claims description 5
- AHQMSKUHOCANHL-UHFFFAOYSA-N 4-[6-(1H-indol-5-yl)pyridin-3-yl]oxy-1-azatricyclo[3.3.1.13,7]decane Chemical compound C1=C2NC=CC2=CC(C2=CC=C(C=N2)OC2C3CN4CC2CC(C4)C3)=C1 AHQMSKUHOCANHL-UHFFFAOYSA-N 0.000 claims description 5
- PIEZNFVNSICXLK-FUHWJXTLSA-N 5-methyl-n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N[C@H]1[C@H](CC=2C=NC=CC=2)N2CCC1CC2 PIEZNFVNSICXLK-FUHWJXTLSA-N 0.000 claims description 5
- PIEZNFVNSICXLK-UHFFFAOYSA-N 5-methyl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound S1C(C)=CC=C1C(=O)NC1C(CC=2C=NC=CC=2)N2CCC1CC2 PIEZNFVNSICXLK-UHFFFAOYSA-N 0.000 claims description 5
- HMBGJHCWZLRYIN-UHFFFAOYSA-N 5-pyridin-2-yl-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C=1C=C(C=2N=CC=CC=2)SC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 HMBGJHCWZLRYIN-UHFFFAOYSA-N 0.000 claims description 5
- TXCYUSKWBHUVEP-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(NC3C4CCN(CC4)C3)=O)=NNC2=C1 TXCYUSKWBHUVEP-UHFFFAOYSA-N 0.000 claims description 5
- BAJXGRSDFUMTTO-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(trifluoromethoxy)-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=NNC2=CC=C(OC(F)(F)F)C=C21 BAJXGRSDFUMTTO-UHFFFAOYSA-N 0.000 claims description 5
- BAJXGRSDFUMTTO-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(trifluoromethoxy)-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NNC2=CC=C(OC(F)(F)F)C=C21 BAJXGRSDFUMTTO-ZDUSSCGKSA-N 0.000 claims description 5
- BAJXGRSDFUMTTO-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-(trifluoromethoxy)-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=CC=C(OC(F)(F)F)C=C21 BAJXGRSDFUMTTO-CYBMUJFWSA-N 0.000 claims description 5
- OXKRFEWMSWPKKV-UHFFFAOYSA-N n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide Chemical compound C=1C2=CC=CC=C2OC=1C(=O)NC1C(CC2)CCN2C1CC1=CC=CN=C1 OXKRFEWMSWPKKV-UHFFFAOYSA-N 0.000 claims description 5
- ZFLIWLTZPYHUBM-IBGZPJMESA-N n-methyl-1-[5-[(3r)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine]-5'-yl]thiophen-2-yl]methanamine Chemical compound S1C(CNC)=CC=C1C1=CN=C(O[C@]2(C3)C4CCN(CC4)C2)C3=C1 ZFLIWLTZPYHUBM-IBGZPJMESA-N 0.000 claims description 5
- ZFLIWLTZPYHUBM-LJQANCHMSA-N n-methyl-1-[5-[(3s)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine]-5'-yl]thiophen-2-yl]methanamine Chemical compound S1C(CNC)=CC=C1C1=CN=C(O[C@@]2(C3)C4CCN(CC4)C2)C3=C1 ZFLIWLTZPYHUBM-LJQANCHMSA-N 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- RXLOZRCLQMJJLC-UHFFFAOYSA-N ssr-180,711 Chemical compound C1=CC(Br)=CC=C1OC(=O)N1C(CC2)CCN2CC1 RXLOZRCLQMJJLC-UHFFFAOYSA-N 0.000 claims description 5
- UAKZGMMGIMKFMV-RBUKOAKNSA-N 3,5-difluoro-n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound FC1=CC(F)=CC(C(=O)N[C@H]2[C@@H](N3CCC2CC3)CC=2C=NC=CC=2)=C1 UAKZGMMGIMKFMV-RBUKOAKNSA-N 0.000 claims description 4
- UAKZGMMGIMKFMV-UHFFFAOYSA-N 3,5-difluoro-n-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound FC1=CC(F)=CC(C(=O)NC2C(N3CCC2CC3)CC=2C=NC=CC=2)=C1 UAKZGMMGIMKFMV-UHFFFAOYSA-N 0.000 claims description 4
- HMBGJHCWZLRYIN-SIKLNZKXSA-N 5-pyridin-2-yl-n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound C([C@@H]1N2CCC(CC2)[C@H]1NC(=O)C=1SC(=CC=1)C=1N=CC=CC=1)C1=CC=CN=C1 HMBGJHCWZLRYIN-SIKLNZKXSA-N 0.000 claims description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 4
- OXKRFEWMSWPKKV-GHTZIAJQSA-N n-[(2s,3r)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide Chemical compound C([C@@H]1N2CCC(CC2)[C@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-GHTZIAJQSA-N 0.000 claims description 4
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 4
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 claims 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 2
- 208000033409 Narcolepsy type 2 Diseases 0.000 claims 1
- 208000028511 narcolepsy without cataplexy Diseases 0.000 claims 1
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 abstract description 2
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 69
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 69
- 239000000203 mixture Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000006747 infectious mononucleosis Diseases 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000003340 mental effect Effects 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007941 film coated tablet Substances 0.000 description 6
- XRIUCCPKYFVCFO-UHFFFAOYSA-N CCC1CN2CCC1C2 Chemical compound CCC1CN2CCC1C2 XRIUCCPKYFVCFO-UHFFFAOYSA-N 0.000 description 5
- RCEYXLPKIJSYEM-UHFFFAOYSA-N Cc1ccc(C)nc1.Cc1ccc(C)nn1.Cc1cnc(C)nc1 Chemical compound Cc1ccc(C)nc1.Cc1ccc(C)nn1.Cc1cnc(C)nc1 RCEYXLPKIJSYEM-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 108060005714 orexin Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 0 CCCC.[1*]C(C)OC(=O)CC Chemical compound CCCC.[1*]C(C)OC(=O)CC 0.000 description 4
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 4
- 102000002512 Orexin Human genes 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229960001165 modafinil Drugs 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LUKNJAQKVPBDSC-UHFFFAOYSA-N 5-[6-(1-azabicyclo[2.2.2]octan-3-yloxy)pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)OC2C3CCN(C2)CC3)=C1 LUKNJAQKVPBDSC-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010062519 Poor quality sleep Diseases 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000037321 sleepiness Effects 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LUKNJAQKVPBDSC-SFHVURJKSA-N 5-[6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)O[C@@H]2C3CCN(C2)CC3)=C1 LUKNJAQKVPBDSC-SFHVURJKSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000000574 ganglionic effect Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GDJTWWGJXFJUTQ-KRWDZBQOSA-N (3r)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane Chemical compound FC1=CC(C)=CC=C1C(N=N1)=CC=C1O[C@@H]1C(CC2)CCN2C1 GDJTWWGJXFJUTQ-KRWDZBQOSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- RUFBGPCDOFYGTF-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonane-4-carboxylic acid Chemical compound OC(=O)N1CCN2CCC1CC2 RUFBGPCDOFYGTF-UHFFFAOYSA-N 0.000 description 1
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- YGLDQFWPUCURIP-UHFFFAOYSA-N 3h-3-benzazepine Chemical compound C1=CNC=CC2=CC=CC=C21 YGLDQFWPUCURIP-UHFFFAOYSA-N 0.000 description 1
- HEDDSROUHOVUPD-KDOFPFPSSA-N 5-[2-[[(4s,5r)-1-azabicyclo[3.3.1]nonan-4-yl]oxy]pyrimidin-5-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC(C2=CN=C(N=C2)O[C@H]2CCN3CCC[C@@]2(C3)[H])=C1 HEDDSROUHOVUPD-KDOFPFPSSA-N 0.000 description 1
- LEUQBJWNAXGICB-APWZRJJASA-N 5-[2-[[(4s,5r)-1-azabicyclo[3.3.1]nonan-4-yl]oxy]pyrimidin-5-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)O[C@H]2CCN3CCC[C@@]2(C3)[H])=C1 LEUQBJWNAXGICB-APWZRJJASA-N 0.000 description 1
- GGFORAABWCDWAK-KDOFPFPSSA-N 5-[6-[[(4s,5r)-1-azabicyclo[3.3.1]nonan-4-yl]oxy]pyridazin-3-yl]-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC(C2=CC=C(N=N2)O[C@H]2CCN3CCC[C@@]2(C3)[H])=C1 GGFORAABWCDWAK-KDOFPFPSSA-N 0.000 description 1
- HAHGPGNZEBCTCN-APWZRJJASA-N 5-[6-[[(4s,5r)-1-azabicyclo[3.3.1]nonan-4-yl]oxy]pyridazin-3-yl]-1h-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)O[C@H]2CCN3CCC[C@@]2(C3)[H])=C1 HAHGPGNZEBCTCN-APWZRJJASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010056557 Gulf war syndrome Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100029076 Histamine N-methyltransferase Human genes 0.000 description 1
- 108010030471 Histamine N-methyltransferase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HQYLURGLNKLOQJ-XHDPSFHLSA-N [(1s)-1-(2-fluorophenyl)ethyl] n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]carbamate Chemical compound C1([C@@H](OC(=O)N[C@H]2C3CCN(CC3)C2)C)=CC=CC=C1F HQYLURGLNKLOQJ-XHDPSFHLSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- TXCYUSKWBHUVEP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NNC2=C1 TXCYUSKWBHUVEP-ZDUSSCGKSA-N 0.000 description 1
- TXCYUSKWBHUVEP-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 TXCYUSKWBHUVEP-CYBMUJFWSA-N 0.000 description 1
- CMRLNEYJEPELSM-BTQNPOSSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 CMRLNEYJEPELSM-BTQNPOSSSA-N 0.000 description 1
- PFVFVMVVRYVOQC-UHFFFAOYSA-N n-[5-(1h-indol-5-yl)pyrimidin-2-yl]-1-azabicyclo[3.3.1]nonan-4-amine Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)NC2CCN3CC2CCC3)=C1 PFVFVMVVRYVOQC-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000010076 persian gulf syndrome Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to pharmaceutical uses of alpha 7 nicotinic acetylcholine receptor ( ⁇ 7 nAChR) agonists.
- Fatigue is a prolonged state in a subject which is characterized by physical and/or mental weakness and is caused by a disorder.
- Said physical weakness is the temporary physical inability of a muscle to perform optimally. It may also be described as muscle exhaustion, muscle weakness, muscle ache or lack of strength and relates to the inability to exert force with one's muscles to the degree that would be expected given the individual's general physical fitness. Central muscle weakness is an overall exhaustion of the whole body, while peripheral weakness is an exhaustion of individual muscles.
- Mental weakness is a temporary inability to maintain optimal cognitive performance. It is characterized by lack of motivation and of alertness. The onset during any cognitive activity is gradual and depends upon an individual's cognitive ability and also upon other factors, such as sleep deprivation and overall health. Mental weakness can manifest itself as sleepiness (decreased wakefulness) or as a general decrease of attention, not necessarily including sleepiness. Decreased attention is also known as “ego depletion” and may be described as a more or less decreased level of consciousness. This may be dangerous when performing tasks that require constant concentration, e.g. driving a vehicle.
- fatigue-like states in subjects may be the result of working, mental stress, overstimulation, understimulation, jet lag, boredom and lack of sleep; said fatigue-like states are not caused by a disorder and are usually reversed by a night's sleep.
- Fatigue can be e.g. chronic fatigue syndrome (CFS).
- CFS chronic fatigue syndrome
- Fatigue can be caused by any of the following disorders: autoimmune diseases such as multiple sclerosis (MS), celiac disease and spondyloarthropathy; infectious diseases, such as HIV infection or infectious mononucleosis; blood disorders, such as anemia and hemochromatosis; cancer (in which case it is also called cancer fatigue); drug abuse, including alcohol abuse; depression or other mental disorders that feature depressed mood; eating disorders (which can produce fatigue due to inadequate nutrition); endocrine diseases, e.g. diabetes mellitus and hypothyroidism; fibromyalgia; Gulf War Syndrome; heart disease; irritable bowel syndrome; inborn errors of metabolism, e.g.
- MS multiple sclerosis
- celiac disease and spondyloarthropathy infectious diseases, such as HIV infection or infectious mononucleosis
- blood disorders such as anemia and hemochromatosis
- cancer in which case it is also called cancer fatigue
- drug abuse including alcohol abuse; depression or other mental disorders that feature depressed mood;
- fructose malabsorption liver failure; leukemia; lymphoma; Lyme disease; neurological disorders, e.g. Parkinson's disease and post-concussion syndrome; physical trauma and other pain-causing conditions, such as arthritis; uremia which is caused by kidney disease; and stroke.
- Fatigue can also be indirectly caused by a disorder, e.g. can be a side effect of medications used to treat a disorder, e.g. lithium salts; ciprofloxacin; beta blockers, which can induce exercise intolerance; and cancer treatments, e.g. chemotherapy and radiotherapy.
- a disorder e.g. lithium salts; ciprofloxacin; beta blockers, which can induce exercise intolerance; and cancer treatments, e.g. chemotherapy and radiotherapy.
- ⁇ 7 nAChR agonists may be used in the treatment (whether therapeutic or prophylactic), prevention, amelioration or delay of progression of fatigue.
- a first aspect of the invention concerns the use of an ⁇ 7 nAChR agonist for the treatment, amelioration, prevention or delay of progression of fatigue;
- ⁇ 7 nAChR agonist is (i) a compound of formula (I)
- L 1 is —CH 2 —; L 2 is —CH 2 —CH 2 —; and L 3 is —CH 2 — or —CH(CH 3 )—; or L 1 is —CH 2 —CH 2 —; L 2 is —CH 2 —; and L 3 is —CH 2 —CH 2 —; L 4 is a group selected from
- R 1 is methyl
- X 1 is —O— or —NH—
- a 2 is selected from
- a 1 is phenyl, indole or 1,3-dihydro-indol-2-one, which may be substituted once or more than once by R 2 , each R 2 independently is C 1-6 alkyl- C 1-6 halogenalkyl or halogen; or (ii) a compound selected from the group consisting of 4-(5-phenyl-1,3,4-thiadiazol-2 -yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane; (4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane; 4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane; 4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decan
- a further aspect of the invention relates to a method for the treatment, amelioration, prevention or delay of progression of fatigue in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the ⁇ 7 nAChR agonist of the invention.
- a further aspect of the invention relates to the use of the ⁇ 7 nAChR agonist of the invention for the manufacture of a medicament for the treatment, amelioration, prevention or delay of progression of fatigue.
- an “ ⁇ 7 nAChR agonist” is a compound that binds to a receptor comprising an ⁇ 7 nAChR subunit in vivo and in vitro and is activating the receptor. Activation can be measured by the method disclosed in WO2001/85727, i.e. a functional affinity assay at the homomeric ⁇ 7 nAChR carried out with a rat pituitary cell line stably expressing the ⁇ 7 nAChR.
- ⁇ 7 nAChR agonists of the invention typically induce calcium influx of at least 50% of the maximal influx evoked by epibatidine with an EC 50 value of at least 1 ⁇ M.
- the ⁇ 7 nAChR agonist of the invention is selective for a receptor comprising a nicotinic acetylcholine receptor alpha 7 subunit, since such an agonist would be expected to cause fewer side effects than a non-selective agonist to a treated subject.
- An agonist being selective for a receptor comprising a nicotinic acetylcholine receptor alpha 7 subunit has a functional affinity to such a receptor to a much higher degree, e.g. at least 10-fold affinity difference in EC 50 value, preferably at least 20-fold, more preferably at least 50-fold, compared to any other nicotinic acetylcholine receptor.
- a similar functional assay is carried out using a human embryonic kidney cell line stable expressing the human ⁇ 4 ⁇ 2 subtype and to assess the activity of the compounds of the invention on the “ganglionic subtype” and the “muscle type” of nicotinic acetylcholine receptor, similar functional assays are carried out with a human embryonic kidney cell line stably expressing the human “ganglionic subtype” or a cell line endogenously expressing the human “muscle type” of nicotinic acetylcholine receptors.
- ⁇ 7 nAChR agonists and their use as pharmaceuticals are known, for example, from WO2001/85727, WO2004/022556, WO2005/118535, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476 and WO2007/068475.
- the “ ⁇ 7 nAChR agonist of the invention” is
- L 1 is —CH 2 —; L 2 is —CH 2 —CH 2 —; and L 3 is —CH 2 — or —CH(CH 3 )—; or L 1 is —CH 2 —CH 2 —; L 2 is —CH 2 —; and L 3 is —CH 2 —CH 2 —; L 4 is a group selected from
- R 1 is methyl
- X 1 is —O— or —NH—
- a 2 is selected from
- a 1 is phenyl, indole or 1,3-dehydro-indol-2-one, which may be substituted once or more than once by R 2 , each R 2 independently is C 1-6 alkyl, C 1-6 halogenalkyl or halogen; or (ii) a compound selected from the group consisting of 4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane; (4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane; 4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane; 4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)
- Alkyl represents a straight-chain or branched-chain alkyl group, for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or Cert-butyl, n-pentyl, n-hexyl;
- C 1-6 alkyl preferably represents a straight-chain or branched-chain C 1-4 alkyl with particular preference given to methyl, ethyl, n-propyl, iso-propyl and tert-butyl.
- alkyl part of “halogenalkyl” shall have the same meaning as described in the above-mentioned definition of “alkyl”, especially regarding linearity and preferential size,
- a substituent being substituted “once or more than once”, for example as defined for A 1 is preferably substituted by one to three substituents.
- Halogen is generally fluorine, chlorine, bromine or iodine; preferably fluorine, chlorine or bromine.
- Halogenalkyl groups preferably have a chain length of 1 to 4 carbon atoms and are, for example, fluoromethyl, difluoromethyl, trifluorornethyl, chloromethyl, dichloromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, 2-chloroethyl, pentafluoroethyl, 1,1-difluoro-2,2,2-trichloroethyl, 2,2,2-trichloroethyl, 1,1,2,2-tetrafluoroethyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl or 2,2,3,4,4,4-hexafluorobutyl; preferably —CF 3 , —CHF 2 , —CH 2 F,
- a 1 or A 3 as a “five- to ten-membered monocyclic or fused polycyclic aromatic ring system” encompasses a C 6 - or C 10 -aromatic
- the acid addition salt forms of the ⁇ 7 nAChR agonists of the invention are preferably pharmaceutically acceptable salt forms.
- Such salts are known in the field (e.g. S. M. Berge, et al, “Pharmaceutical Salts”, J. Pharm. Sd., 1977, 66:1-19; and “Handbook of Pharmaceutical Salts, Properties, Selection, and Use”, Stahl, R H., Wermuth, C. G., Eds.; Wiley-VCH and VHCA: Zurich, 2002).
- a “pharmaceutically acceptable salt form” is intended to mean a salt form that is not toxic, biologically intolerable, or otherwise biologically undesirable.
- the compounds of formula (I) may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. Unless stated otherwise, all optical isomers and their mixtures, including racemic mixtures, are part of the present invention.
- the ⁇ 7 nAChR agonist of the invention is a compound of formula (I)
- a 1 is phenyl, which may be substituted once or more than once by R 2 , each R 2 independently is C 1-6 alkyl, C 1-6 halogenalkyl or halogen; in free base form or in acid addition salt form.
- the a7 nAChR agonist of the invention is a compound selected from Group P1 in free base form or in acid addition salt form, wherein Group P1 is the group consisting of
- A-1 (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester; B-1: (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; B-2: (R)-3-[6-(2-fluoro-4-methyl-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane: B-3: (R)-3-[6-(2,5-difluoro-4-methyl-pherlyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; B-4: (2S,3R)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-2-methy-1-
- the ⁇ 7 nAChR agonist of the invention is a compound selected from Group P2 in free base form or in acid addition salt form, wherein Group P2 is the group consisting of
- D-1a (4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane
- D-1b 4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane
- D-1c 4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane
- D-1d 4-(5-(1H-indol-5-yl)-pyrimidin-2-yloxy)-1azatricyclo[3.3.1.1 3,7 ]decane
- D-2 N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
- D-2a N-((3R)-1-azabicyclo[2.2.2]oct-3-
- D-8a N-methyl-1- ⁇ 5-[(2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl ⁇ methanamine
- D-8b N-methyl-1- ⁇ 5-[(2S)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl ⁇ methanamine
- D-9 (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
- D-10a 5- ⁇ 5-[(endo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl ⁇ -1H-indole
- D-10b 5- ⁇ 5-[(exo)-8-azabicy
- the ⁇ 7 nAChR agonist of the invention is compound A-1 in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound selected from the group consisting of compound B-1, B-2, B-3 and B-4; wherein each of said compound is in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound B-1 in free base form or in acid addition salt form.
- the ⁇ 7-nAChR agonist of the invention is compound B-1, which is in fumarate salt form.
- the ⁇ 7-nAChR agonist of the invention is the mono-fumarate salt of compound B-1,
- the ⁇ 7 nAChR agonist of the invention is a compound B-4 in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound selected from the group consisting of compound C-1, C-2, C-3, C-4 and C-5; wherein each of said compound is in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound C-3 in free base form or in acid addition salt form,
- the ⁇ 7 nAChR agonist of the invention is a compound C-4 in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound C-5 in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound selected from the group consisting of compound D-1, D-1a, D-1b, D-1c, D-1d, D-4, D-4a and D-9; wherein each of said compound is in free base form or in acid addition salt form.
- the ⁇ 7 nAChR agonist of the invention is a compound selected from Group P3;
- Group P3 is the group consisting of compounds A-1, B-1, B-2, B-3, B-4, C-1, C-2, C-3, C-4, C-5, D-1, D-1a, D-1b, D-1c, D-1d, D-4, D-4a and D-9; wherein each of said compound is in free base form or in acid addition salt form.
- the compounds of formula (I) (e.g. compounds A-1, B-1 to B-4 and C-1 to C-5) and their manufacture are known from WO2001/85727, WO2004/022556, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476 and WO2007/068475, or can be prepared analogously to said references.
- Compounds D-1 and D-1a can be prepared according to WO2008/058096.
- Compounds D-2, D-2a, D-2b, D-3, D-3a and D-3b can be prepared according to WO2004/029050 and/or WO2010/043515.
- Compounds D-4 and D-4a can be prepared according to WO2004/076449 and/or WO2009/018505;
- Compounds D-5, D-5a to D-5e can be prepared according to WO2004/076449 and/or WO2010/085724 and/or WO2010/056622;
- Compound D-6 (varenicline) is described in O'Donnell et al, J Med Chem, 2010, 53, 1222-1237.
- Compound D-7 (GTS-21) is described in Haydar et al, Current Topics in Medicinal Chemistry, 2010, 10, 144-152.
- Compound D-8, D-8a and D-8b are described in WO2007/133155 and/or WO02009/066107.
- Compound D-9 is described in WO02003/055878.
- Compounds D-10a to D-10f are described in WO2007/137030.
- Compound D-11 (AZD-0328) is described in Haydar et al, Current Topics in Medicinal Chemistry, 2010, 10, 144-152.
- Compound D-12 (SSR-190771) is described Horenstein et al, Mol Pharmacol, 2008, 74, 1496-1511.
- Compound D-13 (ABT-107) can be prepared according to WO2006/065233 and/or WO2007/018738,
- “Fatigue” as used herein refers to a prolonged state in a subject which is characterized by physical and/or mental weakness and is caused by a disorder.
- fatigue is present in a subject for more than one day.
- fatigue is present in a subject for more than one week.
- fatigue is present in a subject for more than one month.
- CFS chronic fatigue syndrome
- MS multiple sclerosis
- infectious diseases e.g. HIV infection.
- Fatigue has an onset (i.e. is not lifelong) and at least some of the following criteria should be present: (i) a significant reduction of previous activity levels; (ii) impaired memory or concentration; (iii) post-exertional malaise, where physical or mental exertions bring on extreme, prolonged exhaustion and sickness; (iv) unrefreshing sleep; (v) muscle pain; (vi) pain in muscle joints; (vii) headaches of new kind of severity; (viii) frequent or recurring sore throat; or (ix) cervical or axillary tender lymph nodes.
- At least four of the above criteria are present in fatigue.
- At least five of the above criteria are present in fatigue.
- At least six of the above criteria are present in fatigue.
- Fatigue can be e.g. chronic fatigue syndrome (CFS), fatigue associated with MS or fatigue associated with an infectious disease, e.g. HIV infection.
- CFS chronic fatigue syndrome
- MS fatigue associated with MS
- an infectious disease e.g. HIV infection.
- subject refers to a human being, especially to a patient suffering from fatigue, e.g. CFS or fatigue associated with MS.
- treatment refers to any type of treatment that imparts a benefit to a subject, especially a patient, suffering from fatigue, including a reduction of one or more characteristics associated with fatigue or prevention/delay of the onset/progression of fatigue (e.g. prophylactic treatment).
- terapéuticaally effective amount typically refers to a drug amount which, when administered to a subject, is sufficient to provide a therapeutic benefit, e.g. is sufficient for treating, ameliorating, preventing or delaying the progression of fatigue (e.g. the amount provides a amelioration of the characteristics associated with fatigue, e.g. it leads to an increase of activity levels of the subject).
- Treatment may comprise a reduction in the characteristics associated with fatigue, including for example, although not limited to, a reduction in the degree of physical and/or mental weakness; a reduction in the number of fatigue attacks; an improvement in the well-being of the subject; an improvement in the ability to carry out normal tasks; an improved ability to drive cars and operate machines, and/or an increased period of time between fatigue attacks.
- One aspect of the treatment of fatigue is that said treatment should be efficacious and have a minimal adverse effect on the patient, e.g. the drug used should have a high level of cardiac safety.
- Amantadine is approved for Parkinson's disease, as well as some viral infections, Research regarding its use in treating fatigue associated with MS is not conclusive. Side effects can include insomnia and vivid dreams.
- Modafinil is used to treat narcolepsy, a sleep disorder which causes people to sleep excessively during the day.
- narcolepsy a sleep disorder which causes people to sleep excessively during the day.
- side effects can include insomnia and headaches,
- Prokarin is a skin patch that contains caffeine and histamine. Reported side effects are rashes at the side of the patch,
- Antidepressants are also used as many people who have chronic fatigue syndrome are also depressed. Low doses of some antidepressants can help improve sleep and relieve pain, but have limited overall efficacy.
- Highly relevant would be e.g. an agent that can be used to treat fatigue without producing the side effects of the above treatment regiments.
- the ⁇ 7 nAChR agonists of the invention may be used to delay or prevent the onset of fatigue, e.g. in MS patients.
- the appropriate dosage will vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition/symptom being treated.
- a daily dosage of from 0.1 to 100 mg/kg body weight, preferably from 1 to 50 mg/kg body weight, e.g. 10 mg/kg.
- an indicated daily dosage is in the range from 0.5 to 500 mg, preferably from 1 to 100 mg, most preferably from 2 to 75 mg, e.g. 50 mg of an ⁇ 7 nAChR agonist of the invention conveniently administered, for example, in divided doses up to four times a day,
- the daily dosage of the ⁇ 7 nAChR agonist of the invention is from 1 to 100 mg.
- the daily dosage of the ⁇ 7 nAChR agonist of the invention is from 2 to 75 mg.
- the daily dosage of the ⁇ 7 nAChR agonist of the invention is about 50 mg.
- CFS Quality of life is severely disrupted by CFS.
- CFS typically has a sudden onset usually accompanied by a flu-like illness and a significant proportion of cases begin within several months of severe adverse stress.
- CFS may also be caused by viral or non-viral pathogen infection.
- Most commonly used diagnostic criteria were published by the United States Centers for Disease Control and Prevention (CDC). CDC recommends the following three criteria to be fulfilled:
- MS multiple sclerosis
- Fatigue associated with MS may be caused by sleep deprivation (e.g. due to bladder dysfunction or nocturnal muscle spasms producing night-time awakenings); depression; or general disabilities (i.e. the patient needs considerable effort to accomplish daily tasks). Additionally fatigue can be associated with MS but cannot be directly correlated with sleep deprivation, depression or general disability; this type of fatigue associated with MS is also referred to as “lassitude”.
- Fatigue associated with MS typically has the following characteristics: it generally occurs on a daily basis, may occur early in the morning, even after a restful night's sleep, tends to worsen as the day progresses, tends to be aggravated by heat and/or humidity, comes on easily and suddenly, is generally more severe than fatigue not associated with MS and is more likely to interfere with daily responsibilities.
- the ⁇ 7 nAChR agonist of the invention may be administered as single active agent or in combination with other active agents, in any usual manner, e.g. orally, for example in the form of tablets or capsules, parenterally, for example in the form of injection solutions or suspensions, or transdermally, for example in the form of a patch.
- the manner of administration is oral administration, for example in the form of tablets or capsules.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an ⁇ 7 nAChR agonist of the invention in association with at least one pharmaceutical carrier or diluent for the treatment, amelioration, prevention or delay of progression fatigue.
- Such compositions may be manufactured in conventional manner.
- Unit dosage forms may contain, for example, from about 2.5 to about 25 mg of one or more of the ⁇ 7 nAChR agonist of the invention.
- compositions for enteral such as nasal, rectal or oral; parenteral, such as intramuscular or intravenous; or transdermal (e.g. by a patch) administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier.
- the dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
- compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
- Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, drag-es, tablets or capsules.
- compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes. Such processes are exemplified in WO 2005/079802, WO 2003/047581, WO 2004/000316, WO 2005/044265, WO 2005/044266, WO 2005/044267, WO 2006/114262 and WO 2007/071358.
- compositions for transdermal are described in Remington's Pharmaceutical Sciences 16 th Edition Mack; Sucker, Fuchs and Spieser, Pharmazeutician Technologie, 1 st Edition, Springer.
- Embodiment 1-1 An ⁇ 7 nAChR agonist of the invention for use in the treatment, amelioration, prevention or delay of progression of fatigue; wherein said ⁇ 7 nAChR agonist is a compound selected from Group P1 in free base form or in acid addition salt form.
- Embodiment 1-2 The ⁇ 7 nAChR agonist as defined in embodiment 1-1, wherein the fatigue is fatigue associated with multiple sclerosis.
- Embodiment 1-3 The ⁇ 7 nAChR agonist as defined in embodiment 1-2, wherein the fatigue is fatigue associated with multiple sclerosis and is (i) caused by sleep deprivation, depression or general disabilities or (ii) lassitude.
- Embodiment 1-4 The ⁇ 7 nAChR agonist as defined in embodiment 1-1, wherein the fatigue is chronic fatigue syndrome.
- Embodiment 1-5 The ⁇ 7 nAChR agonist as defined in embodiment 1-1, wherein the fatigue is fatigue associated with an infectious disease.
- Embodiment 1-6 The ⁇ 7 nAChR agonist as defined in embodiment 1-5, wherein the fatigue is fatigue associated with HIV infection.
- Embodiment 1-7 The ⁇ 7 nAChR agonist as defined in any of embodiments 1-1 to 1-6, wherein the daily dosage of said agonist is from 1 to 100 mg.
- Embodiment 2-1 An ⁇ 7 nAChR agonist of the invention for use in the treatment, amelioration, prevention or delay of progression of fatigue; wherein said ⁇ 7 nAChR agonist is a compound selected from Group P2 in free base form or in acid addition salt form.
- Embodiment 2-2 The ⁇ 7 nAChR agonist as defined in embodiment 2-1, wherein the fatigue is fatigue associated with multiple sclerosis.
- Embodiment 2-3 The ⁇ 7 nAChR agonist as defined in embodiment 2-2, wherein the fatigue is fatigue associated with multiple sclerosis and is (i) caused by sleep deprivation, depression or general disabilities or (ii) lassitude.
- Embodiment 2-4 The ⁇ 7 nAChR agonist as defined in embodiment 2-1, wherein the fatigue is chronic fatigue syndrome.
- Embodiment 2-5 The ⁇ 7 nAChR agonist as defined in embodiment 2-1, wherein the fatigue is fatigue associated with an infectious disease.
- Embodiment 2-6 The ⁇ 7 nAChR agonist as defined in embodiment 2-5, wherein the fatigue is fatigue associated with HIV infection.
- Embodiment 2-7 The ⁇ 7 nAChR agonist as defined in any of embodiments 2-1 to 2-6-wherein the daily dosage of said agonist is from 1 to 100 mg.
- Embodiment 3-1 An ⁇ 7 nAChR agonist of the invention for use in the treatment, amelioration, prevention or delay of progression of fatigue; wherein said ⁇ 7 nAChR agonist is a compound selected from Group P3 in free base form or in acid addition salt form.
- Embodiment 3-2 The ⁇ 7 nAChR agonist as defined in embodiment 3-1, wherein the fatigue is fatigue associated with multiple sclerosis.
- Embodiment 3-3 The ⁇ 7 nAChR agonist as defined in embodiment 3-2, wherein the fatigue is fatigue associated with multiple sclerosis and is (i) caused by sleep deprivation, depression or general disabilities or (ii) lassitude.
- Embodiment 3-4 The ⁇ 7 nAChR agonist as defined in embodiment 3-1, wherein the fatigue is chronic fatigue syndrome.
- Embodiment 3-5 The ⁇ 7 nAChR agonist as defined in embodiment 3-1, wherein the fatigue is fatigue associated with an infectious disease.
- Embodiment 3-6 The ⁇ 7 nAChR agonist as defined in embodiment 3-5, wherein the fatigue is fatigue associated with HIV infection.
- Embodiment 3-7 The ⁇ 7 nAChR agonist as defined in any of embodiments 3-1 to 3-6, wherein the daily dosage of said agonist is from 1 to 100 mg.
- Hard gelatin capsules each comprising as active ingredient 0.5, 5 or 25 mg of the mono-fumarate of compound B-1, i.e. of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, can be prepared as follows:
- Film-coated tablets containing e.g. 0.5 mg of the mono-fumarate of (R)-3-(6-(4- may be prepared as follows:
- microcrystalline cellulose e.g. approx. 25%
- sprayed lactose e.g. approx. 68%)
- sodium-carboxymethylcellulose XL e.g. approx. 2
- Aerosil e.g. approx. 0.5%)
- a tumble blender approximately 100-300 rotations
- Pass this mixture through a sieve of approx. 0.5-1.0 mm mesh-size and mix again (approx. 100-300 rotations).
- sodium-stearyl-fumarate e.g. approx. 1.5%) through a handsieve at approx. 0.5-1.0 mm mesh-size and mix in a tumble blender (approx. 30-150 rotations).
- Bilayer film-coated tablets containing e.g. 2.5 mg of the mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane may be prepared as follows:
- microcrystalline cellulose e.g. approx. 26%), sprayed lactose (e.g. approx. 69%), sodium-carboxymethylcellulose XL (e.g. approx. 1.9%) and Aerosil (e.g. approx. 0.5%) and mix in a tumble blender (approx 100-300 rotations). Pass this mixture through a sieve of approx. 0.5-1.0 mm mesh-size and mix again (approx 100-300 rotations). Add the sodium-stearyl-fumarate (e.g. approx. 3%) through a handsieve at approx. 0.5-1.0 mm and mix in a tumble blender (approx 30-150 rotations).
- Film-coated tablets containing e.g. 50 mg of the mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane may be prepared as follows:
- the dosage specific tooling e.g. approx. 15*5.9 mm, round, curved.
- ⁇ 7-nAChR activity To assess ⁇ 7-nAChR activity, a functional assay was employed using GH3 cells that recombinantly expressed human ⁇ 7-nAChR. 40000 cells per well were seeded 48 h prior to the experiment on black 96-well plates (Costar) and incubated at 37° C. in a humidified atmosphere (5% CO 2 /95 air). On the day of the experiment, medium was removed by flicking the plates and replaced with 0.1 ml growth medium containing 0.002 mM Fluo-4, (Molecular Probes) in the presence of 2.5 mM probenecid (Sigma). The cells were incubated at 37° C. in a humidified atmosphere (5% CO2/95 air) for 1 h.
- a functional assay was employed using GH3 cells that recombinantly expressed human ⁇ 7-nAChR. 40000 cells per well were seeded 48 h prior to the experiment on black 96-well plates (Costar) and incubated at 37°
- HBS Hepes-buffered salt solution
- Emax maximal effect in % compared to the epibatidine response
- EC 50 concentration producing half the maximal effect in ⁇ M
- Compound B-1 Compound A-1 ⁇ 7 EC 50 (nM) ⁇ SEM, n 39 ⁇ 4.7, 18 100 ⁇ 7.9, 17 ⁇ 7 E max ⁇ SEM, n 73 ⁇ 4.1%, 18 85 ⁇ 5%, 17 ⁇ 1 ⁇ 1 ⁇ IC 50 (nM) ⁇ SEM, n 10715 ⁇ 1376, 6 159222 ⁇ 4306, 6 ⁇ 4 ⁇ 2 IC 50 (nM) ⁇ SEM, n 3981 ⁇ 770, 6 25119 ⁇ 4794, 5 ⁇ 3 ⁇ 4 IC 50 (nM ) ⁇ SEM, n 5248 ⁇ 609, 5 23097 ⁇ 4123, 6 5-HT 3 IC 50 (nM) ⁇ SEM, n 19054 ⁇ 3811, 6 22324 ⁇ 5869, 2
- mice with a knockout of the orexin peptide gene Male transgenic mice with a knockout of the orexin peptide gene are used. Orexin-deficient mice express a phenotype with cataplexy events (observed as ‘behavioral arrests’) and a disrupted sleep pattern including fragmented sleep and sleepiness in their active period.
- mice are observed and videotaped via infrared cameras during the first hours of the lights-off period which is the active phase of nocturnal rodents like mice.
- orexin-deficient mice show the most ‘behavioral arrests’.
- the number of these events can be furthermore increased by presenting a new environment. For this purpose, new saw dust, a running wheel, marbles and tunnels are placed in the test environment.
- the number of ‘behavioral arrests’ are offline counted by the experimenter for each hour of recording. Behavioral arrests were defined by phases of total inactivity outside the next box, which last longer than 10 second, preceded and followed by robust locomotor activity (see also Scammell et al., 2009, Sleep 32(1): 111-116).
- Some of the animals have temporal skull EEG electrodes implanted which are connected to transmitters. The EEG is recorded via a receiver and stored on a PC for further analysis. EEG is used to assess and to quantify sleep behavior and vigilance stage.
- a cross-over design is used because of the high inter- and intra-individual variability of the behaviors to be observed, Furthermore, to avoid habituation to the test environment, the animals are only tested once per week in the test environment. During the remaining days, the animals are in their homecage.
- mice are put into the test environment 3 hours before lights-off.
- the first experimental session (week 1) is used to get a baseline (without treatment).
- the second and third sessions (weeks 2+3) are used for treatment (vehicle & compound, cross-over design, administration 5 minutes before lights-off).
- the fourth and last experimental session is again without treatment to evaluate a post-treatment baseline.
- FIG. 1 depicts the effects of 3 mg/kg compound B-4, orally administered directly before lights-off, on the number of narcoleptic episodes (behavioral arrests) in orexin-deficient mice.
- FIG. 2 depicts the effects of 10 mg/kg compound B-1, orally administered directly before lights-off, on the number of narcoleptic episodes (behavioral arrests) in orexin-deficient mice.
- Compound B-1 significantly decreased the number of narcoleptic episodes during the first hour of the observation period by ca. 66% (p ⁇ 0.05 Anova).
- Animals have temporal skull EEG electrodes implanted which are connected to transmitters. Animals were group-housed (2 - 4) per cage at a constant temperature of 22 ⁇ 1° C., on a 12:12 light-dark schedule. The EEG is recorded via a receiver and stored on a PC for further analysis. EEG is used to assess and to quantify sleep behavior and vigilance stage.
- Compound B-1 causes a decline of NREM sleep and increases the time spent in quiet wake.
- the numerical assessment of FIG. 3 is given in table 1.
- HA Histamine
- tMHA tele-methylhistamine
- FIG. 4 depicts the effects of different doses of compound B1 and A-1, orally administered to mice, 30 minutes after administration on brain tMHA levels. tMHA levels are significantly elevated for compound B-1 at all doses tested. For compound A-1 a significant elevation is seen for the 10 mg/kg dose.
- Clinical testing of the ⁇ 7 nAChA agonist of the invention may be conducted, for example, in one of the following study designs.
- the skilled physician may look at a number of aspects of patient behaviors and abilities, He will realize that such studies are considered as guidelines and the certain aspects of the studies may be modified and redefined depending on the circumstance and environment, for example.
- a patient population, with a normal control is dosed once a day for a week or longer tested.
- the test is designed to allow for improvement, i.e. that there is a measurable parameter increase of the impaired function.
- the patients are tested at the beginning and at the end of the dosage period and the results are compared and analyzed.
- a patient population with fatigue e.g. fatigue associated with MS is dosed once a day for 12 weeks or longer and tested.
- the test is designed to allow for improvement, i.e. that there is a measurable parameter increase of the impaired domain.
- Examples of those tests include cognitive testing, the fatigue scale for motor and cognitive functions (FMC), Paced Auditory Serial Addition Test (PASAT), change in fatigue as measured on a visual analog scale (VAS), Fatigue Severity Scale (FSS) ,Neurological status as measured with the Expanded Disability Status Scale (EDSS) and Quality Of Life among others
- the patients are tested at the beginning and at the end of the dosage period and the results are compared and analyzed.
- FIG. 1 Behavioral arrest, compound B-4
- FIG. 2 Behavioral arrest, compound B-1
- FIG. 3 EEG Measurements, compound B-1
- FIG. 4 Telemethyl histamine measurements, compounds B-1 and A-1
- a further aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the ⁇ 7 nAChR agonist of the invention for the treatment, amelioration, prevention or delay of progression of fatigue.
- a further aspect of the invention relates to a kit comprising an ⁇ 7 nAChR agonist of the invention and instructions for using the agonist in the treatment, amelioration, prevention or delay of progression of fatigue in a subject in need of such treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to pharmaceutical uses of alpha 7 nicotinic acetylcholine receptor (α7 nAChR) agonists.
- Fatigue is a prolonged state in a subject which is characterized by physical and/or mental weakness and is caused by a disorder.
- Said physical weakness is the temporary physical inability of a muscle to perform optimally. It may also be described as muscle exhaustion, muscle weakness, muscle ache or lack of strength and relates to the inability to exert force with one's muscles to the degree that would be expected given the individual's general physical fitness. Central muscle weakness is an overall exhaustion of the whole body, while peripheral weakness is an exhaustion of individual muscles.
- Mental weakness is a temporary inability to maintain optimal cognitive performance. It is characterized by lack of motivation and of alertness. The onset during any cognitive activity is gradual and depends upon an individual's cognitive ability and also upon other factors, such as sleep deprivation and overall health. Mental weakness can manifest itself as sleepiness (decreased wakefulness) or as a general decrease of attention, not necessarily including sleepiness. Decreased attention is also known as “ego depletion” and may be described as a more or less decreased level of consciousness. This may be dangerous when performing tasks that require constant concentration, e.g. driving a vehicle.
- Although similar, fatigue-like states in subjects may be the result of working, mental stress, overstimulation, understimulation, jet lag, boredom and lack of sleep; said fatigue-like states are not caused by a disorder and are usually reversed by a night's sleep.
- Fatigue can be e.g. chronic fatigue syndrome (CFS).
- Fatigue can be caused by any of the following disorders: autoimmune diseases such as multiple sclerosis (MS), celiac disease and spondyloarthropathy; infectious diseases, such as HIV infection or infectious mononucleosis; blood disorders, such as anemia and hemochromatosis; cancer (in which case it is also called cancer fatigue); drug abuse, including alcohol abuse; depression or other mental disorders that feature depressed mood; eating disorders (which can produce fatigue due to inadequate nutrition); endocrine diseases, e.g. diabetes mellitus and hypothyroidism; fibromyalgia; Gulf War Syndrome; heart disease; irritable bowel syndrome; inborn errors of metabolism, e.g. fructose malabsorption; liver failure; leukemia; lymphoma; Lyme disease; neurological disorders, e.g. Parkinson's disease and post-concussion syndrome; physical trauma and other pain-causing conditions, such as arthritis; uremia which is caused by kidney disease; and stroke.
- Fatigue can also be indirectly caused by a disorder, e.g. can be a side effect of medications used to treat a disorder, e.g. lithium salts; ciprofloxacin; beta blockers, which can induce exercise intolerance; and cancer treatments, e.g. chemotherapy and radiotherapy.
- There is a need for new pharmacological compounds that effectively target fatigue.
- It has been found that certain α7 nAChR agonists may be used in the treatment (whether therapeutic or prophylactic), prevention, amelioration or delay of progression of fatigue.
- Accordingly, a first aspect of the invention concerns the use of an α7 nAChR agonist for the treatment, amelioration, prevention or delay of progression of fatigue;
- wherein said α7 nAChR agonist is
(i) a compound of formula (I) - wherein
L1 is —CH2—; L2 is —CH2—CH2—; and L3 is —CH2— or —CH(CH3)—; or
L1 is —CH2—CH2—; L2 is —CH2—; and L3 is —CH2—CH 2—;
L4 is a group selected from - wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;
R1 is methyl; - A2 is selected from
- wherein the bond marked with the asterisk is attached to X1;
A1 is phenyl, indole or 1,3-dihydro-indol-2-one, which may be substituted once or more than once by R2, each R2 independently is C1-6alkyl- C1-6halogenalkyl or halogen; or
(ii) a compound selected from the group consisting of
4-(5-phenyl-1,3,4-thiadiazol-2 -yloxy)-1azatricyclo[3.3.1.13,7]decane;
(4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.13,7]decane;
4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)-1azatricyclo[3.3.1.13,7]decane;
4-(5-(1H-indol-5-yl)-pyrimidin-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide;
N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
N-(1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)berizofuran-2-carboxamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
(2S,3R)-N-(2-((3-pyridinyl)rnethyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino-(2,3-h)(3)-benzazepine;
3-[1-(2,4-Dimethoxy-phenyl)-meth-(E)-ylidene]-3,4,5,6-tetrahydro-[2,3′]bipyridinyl;
N-methyl-1-{5-[3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
N-methyl-1-{5-[(2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
N-methyl-1-{5-[(2S)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide;
5-{5-[(endo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole:
5-{5-[(exo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;
5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole:
5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole:
4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole;
5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-3-yl}-1H-indole;
(2′R)-spiro-[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine];
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic add 4-bromo-phenyl ester; and
5-{6-[1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole:
in tree base form or in add addition salt form. - A further aspect of the invention relates to a method for the treatment, amelioration, prevention or delay of progression of fatigue in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of the α7 nAChR agonist of the invention.
- A further aspect of the invention relates to the use of the α7 nAChR agonist of the invention for the manufacture of a medicament for the treatment, amelioration, prevention or delay of progression of fatigue.
- As used herein an “α7 nAChR agonist” is a compound that binds to a receptor comprising an α7 nAChR subunit in vivo and in vitro and is activating the receptor. Activation can be measured by the method disclosed in WO2001/85727, i.e. a functional affinity assay at the homomeric α7 nAChR carried out with a rat pituitary cell line stably expressing the α7 nAChR. As read out, the calcium influx upon stimulation of the receptor compared to epibatidine is used, “α7 nAChR agonists of the invention” according to the invention typically induce calcium influx of at least 50% of the maximal influx evoked by epibatidine with an EC50 value of at least 1 μM.
- In one embodiment, the α7 nAChR agonist of the invention is selective for a receptor comprising a nicotinic acetylcholine receptor alpha 7 subunit, since such an agonist would be expected to cause fewer side effects than a non-selective agonist to a treated subject. An agonist being selective for a receptor comprising a nicotinic acetylcholine receptor alpha 7 subunit has a functional affinity to such a receptor to a much higher degree, e.g. at least 10-fold affinity difference in EC50 value, preferably at least 20-fold, more preferably at least 50-fold, compared to any other nicotinic acetylcholine receptor. To assess the affinity of the α7 nAChR agonists of the invention on other nicotinic acetylcholine receptors, the method disclosed in WO2001/85727 can be used, i.e. to assess the affinity on human neuronal α4β2 nAChR, a similar functional assay is carried out using a human embryonic kidney cell line stable expressing the human α4β2 subtype and to assess the activity of the compounds of the invention on the “ganglionic subtype” and the “muscle type” of nicotinic acetylcholine receptor, similar functional assays are carried out with a human embryonic kidney cell line stably expressing the human “ganglionic subtype” or a cell line endogenously expressing the human “muscle type” of nicotinic acetylcholine receptors.
- In the last 15 years much effort has been focused on developing selective α7 nAChR agonists leading to the discovery of many different chemotypes displaying said selective activity. These efforts are summarized the review from Horenstein et al (Mol Pharmacol, 2008, 74, 1496-1511, which describes no less than 9 different families of α7 nAChR agonists, in most of which selective agonists have been found. All compounds disclosed in
FIG. 1 of said review are incorporated herein by reference. In fact, several drug candidates having an α7 nAChR agonist mode of action entered pre-clinical or even clinical testing (for review; Broad et al, Drugs of the Future, 2007, 32(2), 161-170; Romanelli et al, Expert Opin Ther Patents, 2007, 17(11), 1365-1377). Examples of such compounds—again belonging to a diversity of chemotypes—are MEM3454, MEM63908, SSR180711, GTS21, EVP6124, ABT107 and TC-5619. Further α7 nAChR agonists and their use as pharmaceuticals are known, for example, from WO2001/85727, WO2004/022556, WO2005/118535, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476 and WO2007/068475. - The “α7 nAChR agonist of the invention” is
- (i) a compound of formula (I)
- wherein
L1 is —CH2—; L2 is —CH2—CH2—; and L3 is —CH2— or —CH(CH3)—; or
L1 is —CH2—CH2—; L2 is —CH2—; and L3 is —CH2—CH2—;
L4 is a group selected from - wherein the bond marked with the asterisk is attached to the azabicycloalkyl moiety;
R1 is methyl; - A2 is selected from
- wherein the bond marked with the asterisk is attached to X1;
A1 is phenyl, indole or 1,3-dehydro-indol-2-one, which may be substituted once or more than once by R2, each R2 independently is C1-6alkyl, C1-6halogenalkyl or halogen; or
(ii) a compound selected from the group consisting of
4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
(4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.13,7]decane;
4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)-1azatricyclo[3.3.1.13,7]decane;
4-(5-(1H-indol-5-yl)-pyrimidin-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
N-(1-azabicyclo[2,2.2]oct-3-yl)-1H-indazole-3-carboxamide;
N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
N-(1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
(2S,3R)-N-(2-(3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino-(2,3-h)(3)-benzazepine;
3-[1-(2,4-Dimethoxy-phenyl)-meth-(E)-ylidene]-3,4,5,6-tetrahydro-[2,3′]bipyridinyl;
N-methyl-1-{5-[3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
N-methyl-1-{5-[(2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
N-methyl-1-{5-[(2S)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide;
5-{5-[(endo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;
5-{5-[(exo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;
5-{5-[(endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole;
5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole;
4-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole;
5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-3-yl}-1H-indole;
(2′R)-spiro-[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine];
1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-phenyl ester; and
5-{6-[1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole;
in free base form or in acid addition salt form. - Unless indicated otherwise, the expressions used in this invention have the following meaning:
- “Alkyl” represents a straight-chain or branched-chain alkyl group, for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or Cert-butyl, n-pentyl, n-hexyl; C1-6alkyl preferably represents a straight-chain or branched-chain C1-4alkyl with particular preference given to methyl, ethyl, n-propyl, iso-propyl and tert-butyl.
- The alkyl part of “halogenalkyl” and shall have the same meaning as described in the above-mentioned definition of “alkyl”, especially regarding linearity and preferential size,
- A substituent being substituted “once or more than once”, for example as defined for A1, is preferably substituted by one to three substituents.
- Halogen is generally fluorine, chlorine, bromine or iodine; preferably fluorine, chlorine or bromine. Halogenalkyl groups preferably have a chain length of 1 to 4 carbon atoms and are, for example, fluoromethyl, difluoromethyl, trifluorornethyl, chloromethyl, dichloromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, 2-chloroethyl, pentafluoroethyl, 1,1-difluoro-2,2,2-trichloroethyl, 2,2,2-trichloroethyl, 1,1,2,2-tetrafluoroethyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl or 2,2,3,4,4,4-hexafluorobutyl; preferably —CF3, —CHF2, —CH2F, —CHF—CH3, —CF2CH3, or —CH2CF3.
- In the context of the invention, the definition of A1 or A3 as a “five- to ten-membered monocyclic or fused polycyclic aromatic ring system” encompasses a C6- or C10-aromatic
- The acid addition salt forms of the α7 nAChR agonists of the invention are preferably pharmaceutically acceptable salt forms. Such salts are known in the field (e.g. S. M. Berge, et al, “Pharmaceutical Salts”, J. Pharm. Sd., 1977, 66:1-19; and “Handbook of Pharmaceutical Salts, Properties, Selection, and Use”, Stahl, R H., Wermuth, C. G., Eds.; Wiley-VCH and VHCA: Zurich, 2002). A “pharmaceutically acceptable salt form” is intended to mean a salt form that is not toxic, biologically intolerable, or otherwise biologically undesirable.
- On account of asymmetrical carbon atoms) that may be present in the compounds of formula (I), unless stated otherwise, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. Unless stated otherwise, all optical isomers and their mixtures, including racemic mixtures, are part of the present invention.
- In one embodiment, the α7 nAChR agonist of the invention is a compound of formula (I)
- wherein
L1 is —CH2—; L2 is —CH2—CH2—; and L3 is —CH2—;
L4 is L4b;
A2 is selected from - wherein the bond marked with the asterisk is attached to X1;
A1 is phenyl, which may be substituted once or more than once by R2, each R2 independently is C1-6alkyl, C1-6halogenalkyl or halogen; in free base form or in acid addition salt form. - In one embodiment, the a7 nAChR agonist of the invention is a compound selected from Group P1 in free base form or in acid addition salt form, wherein Group P1 is the group consisting of
- A-1: (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester;
B-1: (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane;
B-2: (R)-3-[6-(2-fluoro-4-methyl-phenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane:
B-3: (R)-3-[6-(2,5-difluoro-4-methyl-pherlyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane;
B-4: (2S,3R)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-2-methy-1-aza-bicyclo[2.2.2]octane;
C-1: (4S,5R)-4-[5-(1H-indol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane;
C-2: 5-{2-[(4S,5R)-(1-aza-bicyclo[3.3.1]non-4-yl)oxy]-pyrimidin-5-yl}-1,3-dihydro-indol-2-one:
C-3: (4S,5R)-4-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[3.3.1]nonane;
C-4: 5-{6-[(4S,5R)-(1-aza-bicyclo[3.3.1]non-4-yl)oxy]-pyridazin-3-yl}-1,3-dihydro-indol-2-one; and
C-5: (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-pyrimidin-2-yl]-amine. - In one embodiment, the α7 nAChR agonist of the invention is a compound selected from Group P2 in free base form or in acid addition salt form, wherein Group P2 is the group consisting of
- D-1: 4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.13,7]decane having the formula
- D-1a: (4S)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
D-1b: 4-(6-(1H-indol-5-yl)-pyridazin-3-yloxy)-1azatricyclo[3.3.1.13,7]decane;
D-1c: 4-(6-(1H-indol-5-yl)-pyridin-3-yloxy)-1azatricyclo[3.3.1.13,7]decane;
D-1d: 4-(5-(1H-indol-5-yl)-pyrimidin-2-yloxy)-1azatricyclo[3.3.1.13,7]decane;
D-2: N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide;
D-2a: N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
D-2b: N-((3S)-1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
D-3: N-(1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
D-3a: N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
D-3b: N-((3S)-1-azabicyclo[2.2,2]oct-3-yl)-5-(trifluoromethoxy)-1H-indazole-3-carboxamide;
D-4: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
D-4a: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide;
D-5: N-(2-((3-pyridnyl)methyl)-1-azobicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
D-5a: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide;
D-5b: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide:
D-5c: (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide;
D-5d: N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
D-5e: (2S-3R)-N-(2-((3-pyridinyl)rnethyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-pyridinyl)thiophene-2-carboxamide;
D-6: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazine-(2,3-h)(3)-benzazepine;
D-7: 3-[1-(2,4-Dimethoxy-phenyl)-meth-(E)-ylidene]-3,4,5,6-tetrahydro-[2,3′]bipyridinyl;
D-8: N-methyl-1-{5-[3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine having the formula - D-8a: N-methyl-1-{5-[(2R)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
D-8b: N-methyl-1-{5-[(2S)-3′H-spiro[4-azabicyclo[2.2.2]octane-2,2′-furo[2,3-b]pyridin]-5′-yl]-2-thienyl}methanamine;
D-9: (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide;
D-10a: 5-{5-[(endo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole;
D-10b: 5-{5-[(exo)-8-azabicyclo[3.2.1]octan-3-yloxy]pyridin-2-yl}-1H-indole:
D-10c: 5-{5-[(endo)-8-methyl-8-aza-bicycio[3.2.1]oct-3-yioxy]pyridin-2-yl}-1H-indole:
D-10d: 5-{5-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole;
D-10e: 4-{5-[(exo)-8-methyl-8-aza-bicycle[3.2.1]oct-3-yloxy]pyridin-2-yl}-1H-indole;
D-10f: 5-{6-[(exo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy]pyridin-3-yl}-1H-indole;
D-11: (2′R)-spiro-[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine];
D-12: 1,4-Diaza-bicyclo[3.2.2]nonane-4-carboxylic acid 4-bromo-phenyl ester; and
D-13: 5-{6-[1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole. - In one embodiment, the α7 nAChR agonist of the invention is compound A-1 in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound selected from the group consisting of compound B-1, B-2, B-3 and B-4; wherein each of said compound is in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound B-1 in free base form or in acid addition salt form. In another embodiment, the α7-nAChR agonist of the invention is compound B-1, which is in fumarate salt form. In yet another embodiment, the α7-nAChR agonist of the invention is the mono-fumarate salt of compound B-1,
- In one embodiment, the α7 nAChR agonist of the invention is a compound B-4 in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound selected from the group consisting of compound C-1, C-2, C-3, C-4 and C-5; wherein each of said compound is in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound C-3 in free base form or in acid addition salt form,
- In one embodiment, the α7 nAChR agonist of the invention is a compound C-4 in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound C-5 in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound selected from the group consisting of compound D-1, D-1a, D-1b, D-1c, D-1d, D-4, D-4a and D-9; wherein each of said compound is in free base form or in acid addition salt form.
- In one embodiment, the α7 nAChR agonist of the invention is a compound selected from Group P3; Group P3 is the group consisting of compounds A-1, B-1, B-2, B-3, B-4, C-1, C-2, C-3, C-4, C-5, D-1, D-1a, D-1b, D-1c, D-1d, D-4, D-4a and D-9; wherein each of said compound is in free base form or in acid addition salt form.
- The compounds of formula (I) (e.g. compounds A-1, B-1 to B-4 and C-1 to C-5) and their manufacture are known from WO2001/85727, WO2004/022556, WO2005/123732, WO2006/005608, WO2007/045478, WO2007/068476 and WO2007/068475, or can be prepared analogously to said references.
- Compounds D-1 and D-1a can be prepared according to WO2008/058096.
Compounds D-2, D-2a, D-2b, D-3, D-3a and D-3b can be prepared according to WO2004/029050 and/or WO2010/043515.
Compounds D-4 and D-4a can be prepared according to WO2004/076449 and/or WO2009/018505;
Compounds D-5, D-5a to D-5e can be prepared according to WO2004/076449 and/or WO2010/085724 and/or WO2010/056622;
Compound D-6 (varenicline) is described in O'Donnell et al, J Med Chem, 2010, 53, 1222-1237.
Compound D-7 (GTS-21) is described in Haydar et al, Current Topics in Medicinal Chemistry, 2010, 10, 144-152.
Compound D-8, D-8a and D-8b are described in WO2007/133155 and/or WO02009/066107.
Compound D-9 is described in WO02003/055878.
Compounds D-10a to D-10f are described in WO2007/137030.
Compound D-11 (AZD-0328) is described in Haydar et al, Current Topics in Medicinal Chemistry, 2010, 10, 144-152.
Compound D-12 (SSR-190771) is described Horenstein et al, Mol Pharmacol, 2008, 74, 1496-1511.
Compound D-13 (ABT-107) can be prepared according to WO2006/065233 and/or WO2007/018738, - “Fatigue” as used herein refers to a prolonged state in a subject which is characterized by physical and/or mental weakness and is caused by a disorder.
- In one embodiment, fatigue is present in a subject for more than one day.
- In one embodiment, fatigue is present in a subject for more than one week.
- In one embodiment, fatigue is present in a subject for more than one month.
- Disorders causing fatigue are listed above, and may particularly be, e.g. chronic fatigue syndrome (CFS); multiple sclerosis (MS); or infectious diseases, e.g. HIV infection.
- Fatigue has an onset (i.e. is not lifelong) and at least some of the following criteria should be present: (i) a significant reduction of previous activity levels; (ii) impaired memory or concentration; (iii) post-exertional malaise, where physical or mental exertions bring on extreme, prolonged exhaustion and sickness; (iv) unrefreshing sleep; (v) muscle pain; (vi) pain in muscle joints; (vii) headaches of new kind of severity; (viii) frequent or recurring sore throat; or (ix) cervical or axillary tender lymph nodes.
- In one embodiment, at least four of the above criteria are present in fatigue.
- In one embodiment, at least five of the above criteria are present in fatigue.
- In one embodiment, at least six of the above criteria are present in fatigue.
- Fatigue can be e.g. chronic fatigue syndrome (CFS), fatigue associated with MS or fatigue associated with an infectious disease, e.g. HIV infection.
- The term “subject” as used herein refers to a human being, especially to a patient suffering from fatigue, e.g. CFS or fatigue associated with MS.
- The term “treatment” as used herein refers to any type of treatment that imparts a benefit to a subject, especially a patient, suffering from fatigue, including a reduction of one or more characteristics associated with fatigue or prevention/delay of the onset/progression of fatigue (e.g. prophylactic treatment).
- The term “therapeutically effective amount” as used herein typically refers to a drug amount which, when administered to a subject, is sufficient to provide a therapeutic benefit, e.g. is sufficient for treating, ameliorating, preventing or delaying the progression of fatigue (e.g. the amount provides a amelioration of the characteristics associated with fatigue, e.g. it leads to an increase of activity levels of the subject).
- Treatment may comprise a reduction in the characteristics associated with fatigue, including for example, although not limited to, a reduction in the degree of physical and/or mental weakness; a reduction in the number of fatigue attacks; an improvement in the well-being of the subject; an improvement in the ability to carry out normal tasks; an improved ability to drive cars and operate machines, and/or an increased period of time between fatigue attacks.
- One aspect of the treatment of fatigue is that said treatment should be efficacious and have a minimal adverse effect on the patient, e.g. the drug used should have a high level of cardiac safety.
- Although there are currently no drugs approved for fatigue (e.g. fatigue associated with MS or CFS), certain drugs approved for other conditions are sometimes prescribed. Examples include: amantadine, modafinil and Prokarin.
- Amantadine is approved for Parkinson's disease, as well as some viral infections, Research regarding its use in treating fatigue associated with MS is not conclusive. Side effects can include insomnia and vivid dreams.
- Modafinil is used to treat narcolepsy, a sleep disorder which causes people to sleep excessively during the day. There have been several small studies looking at modafinil to treat fatigue associated with MS, but they have had conflicting results and have not proved the benefits of taking modafinil. Side effects can include insomnia and headaches,
- Prokarin is a skin patch that contains caffeine and histamine. Reported side effects are rashes at the side of the patch,
- Antidepressants are also used as many people who have chronic fatigue syndrome are also depressed. Low doses of some antidepressants can help improve sleep and relieve pain, but have limited overall efficacy.
- Highly relevant would be e.g. an agent that can be used to treat fatigue without producing the side effects of the above treatment regiments.
- In the case of prophylactic treatment, the α7 nAChR agonists of the invention may be used to delay or prevent the onset of fatigue, e.g. in MS patients.
- For the above-mentioned treatment methods the appropriate dosage will vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition/symptom being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from 0.1 to 100 mg/kg body weight, preferably from 1 to 50 mg/kg body weight, e.g. 10 mg/kg. In larger mammals, for example humans, an indicated daily dosage is in the range from 0.5 to 500 mg, preferably from 1 to 100 mg, most preferably from 2 to 75 mg, e.g. 50 mg of an α7 nAChR agonist of the invention conveniently administered, for example, in divided doses up to four times a day,
- In one embodiment, the daily dosage of the α7 nAChR agonist of the invention is from 1 to 100 mg.
- In one embodiment, the daily dosage of the α7 nAChR agonist of the invention is from 2 to 75 mg.
- In one embodiment, the daily dosage of the α7 nAChR agonist of the invention is about 50 mg.
- Recent studies have reported between 7 and 3,000 cases of CFS for every 100,000 adults (N Afari and D Buchwald, 2003, “Chronic fatigue syndrome: a review”. Am J Psychiatr, 160(2): 221-36). The wide variance of the prevalence estimates may be due to the different definitions of CFS in use, the settings in which patients were selected, and the methodology used to exclude study participants with possible alternative diagnoses (G Ranjith, 2005, “Epidemiology of chronic fatigue syndrome”. Occup Med (Load) 55 (1): 13-29). The Centers for Disease Control report that more than 1 million Americans have CFS and approximately 30% of the cases are undiagnosed (“Chronic Fatigue Syndrome Basic Facts”, Centers for Disease Control and Prevention. May 9, 2006). Approximately 250,000 people in the UK are affected with the illness according to the National Health Service (“Chronic fatigue syndrome”; The National Health Service, 2009-06-29).
- Quality of life is severely disrupted by CFS. CFS typically has a sudden onset usually accompanied by a flu-like illness and a significant proportion of cases begin within several months of severe adverse stress. CFS may also be caused by viral or non-viral pathogen infection. Most commonly used diagnostic criteria were published by the United States Centers for Disease Control and Prevention (CDC). CDC recommends the following three criteria to be fulfilled:
- 1. A new onset (not lifelong) of severe fatigue for six consecutive months or greater duration which is unrelated to exertion, is not substantially relieved by rest, and is not a result of other medical conditions.
2, The fatigue causes a significant reduction of previous activity levels.
3. Four or more of the following symptoms that last six months or longer: -
- impaired memory or concentration;
- post-exertional malaise, where physical or mental exertions bring on “extreme, prolonged exhaustion and sickness”;
- unrefreshing sleep;
- muscle pain (myalgia);
- pain in multiple joints (arthralgia);
- headaches of a new kind or greater severity;
- sore throat, frequent or recurring; or
- tender lymph nodes (cervical or axillary).
CFS may be persistent or relapsing.
- Up to 75% of multiple sclerosis (MS) patients suffer at some stage during their disease from fatigue associated with multiple sclerosis (Henze et al, European Neurology, 2006, 56, 78-105).
- Fatigue associated with MS may be caused by sleep deprivation (e.g. due to bladder dysfunction or nocturnal muscle spasms producing night-time awakenings); depression; or general disabilities (i.e. the patient needs considerable effort to accomplish daily tasks). Additionally fatigue can be associated with MS but cannot be directly correlated with sleep deprivation, depression or general disability; this type of fatigue associated with MS is also referred to as “lassitude”.
- Fatigue associated with MS typically has the following characteristics: it generally occurs on a daily basis, may occur early in the morning, even after a restful night's sleep, tends to worsen as the day progresses, tends to be aggravated by heat and/or humidity, comes on easily and suddenly, is generally more severe than fatigue not associated with MS and is more likely to interfere with daily responsibilities.
- For use according to the invention, the α7 nAChR agonist of the invention may be administered as single active agent or in combination with other active agents, in any usual manner, e.g. orally, for example in the form of tablets or capsules, parenterally, for example in the form of injection solutions or suspensions, or transdermally, for example in the form of a patch.
- In one embodiment, the manner of administration is oral administration, for example in the form of tablets or capsules.
- Moreover, the present invention provides a pharmaceutical composition comprising an α7 nAChR agonist of the invention in association with at least one pharmaceutical carrier or diluent for the treatment, amelioration, prevention or delay of progression fatigue. Such compositions may be manufactured in conventional manner. Unit dosage forms may contain, for example, from about 2.5 to about 25 mg of one or more of the α7 nAChR agonist of the invention.
- The pharmaceutical compositions according to the invention are compositions for enteral, such as nasal, rectal or oral; parenteral, such as intramuscular or intravenous; or transdermal (e.g. by a patch) administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
- The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, drag-es, tablets or capsules.
- The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes. Such processes are exemplified in WO 2005/079802, WO 2003/047581, WO 2004/000316, WO 2005/044265, WO 2005/044266, WO 2005/044267, WO 2006/114262 and WO 2007/071358.
- Compositions for transdermal are described in Remington's Pharmaceutical Sciences 16th Edition Mack; Sucker, Fuchs and Spieser, Pharmazeutische Technologie, 1st Edition, Springer.
- The following are further embodiments of le invention.
- Embodiment 1-1: An α7 nAChR agonist of the invention for use in the treatment, amelioration, prevention or delay of progression of fatigue; wherein said α7 nAChR agonist is a compound selected from Group P1 in free base form or in acid addition salt form.
- Embodiment 1-2. The α7 nAChR agonist as defined in embodiment 1-1, wherein the fatigue is fatigue associated with multiple sclerosis.
- Embodiment 1-3. The α7 nAChR agonist as defined in embodiment 1-2, wherein the fatigue is fatigue associated with multiple sclerosis and is (i) caused by sleep deprivation, depression or general disabilities or (ii) lassitude.
- Embodiment 1-4. The α7 nAChR agonist as defined in embodiment 1-1, wherein the fatigue is chronic fatigue syndrome.
- Embodiment 1-5. The α7 nAChR agonist as defined in embodiment 1-1, wherein the fatigue is fatigue associated with an infectious disease.
- Embodiment 1-6. The α7 nAChR agonist as defined in embodiment 1-5, wherein the fatigue is fatigue associated with HIV infection.
- Embodiment 1-7. The α7 nAChR agonist as defined in any of embodiments 1-1 to 1-6, wherein the daily dosage of said agonist is from 1 to 100 mg.
- Embodiment 2-1: An α7 nAChR agonist of the invention for use in the treatment, amelioration, prevention or delay of progression of fatigue; wherein said α7 nAChR agonist is a compound selected from Group P2 in free base form or in acid addition salt form.
- Embodiment 2-2. The α7 nAChR agonist as defined in embodiment 2-1, wherein the fatigue is fatigue associated with multiple sclerosis.
- Embodiment 2-3. The α7 nAChR agonist as defined in embodiment 2-2, wherein the fatigue is fatigue associated with multiple sclerosis and is (i) caused by sleep deprivation, depression or general disabilities or (ii) lassitude.
- Embodiment 2-4, The α7 nAChR agonist as defined in embodiment 2-1, wherein the fatigue is chronic fatigue syndrome.
- Embodiment 2-5. The α7 nAChR agonist as defined in embodiment 2-1, wherein the fatigue is fatigue associated with an infectious disease.
- Embodiment 2-6, The α7 nAChR agonist as defined in embodiment 2-5, wherein the fatigue is fatigue associated with HIV infection.
- Embodiment 2-7. The α7 nAChR agonist as defined in any of embodiments 2-1 to 2-6-wherein the daily dosage of said agonist is from 1 to 100 mg.
- Embodiment 3-1: An α7 nAChR agonist of the invention for use in the treatment, amelioration, prevention or delay of progression of fatigue; wherein said α7 nAChR agonist is a compound selected from Group P3 in free base form or in acid addition salt form.
- Embodiment 3-2. The α7 nAChR agonist as defined in embodiment 3-1, wherein the fatigue is fatigue associated with multiple sclerosis.
- Embodiment 3-3. The α7 nAChR agonist as defined in embodiment 3-2, wherein the fatigue is fatigue associated with multiple sclerosis and is (i) caused by sleep deprivation, depression or general disabilities or (ii) lassitude.
- Embodiment 3-4. The α7 nAChR agonist as defined in embodiment 3-1, wherein the fatigue is chronic fatigue syndrome.
- Embodiment 3-5. The α7 nAChR agonist as defined in embodiment 3-1, wherein the fatigue is fatigue associated with an infectious disease.
- Embodiment 3-6. The α7 nAChR agonist as defined in embodiment 3-5, wherein the fatigue is fatigue associated with HIV infection.
- Embodiment 3-7. The α7 nAChR agonist as defined in any of embodiments 3-1 to 3-6, wherein the daily dosage of said agonist is from 1 to 100 mg.
- The following non-limiting examples are illustrative of the disclosure.
- Hard gelatin capsules, each comprising as active ingredient 0.5, 5 or 25 mg of the mono-fumarate of compound B-1, i.e. of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, can be prepared as follows:
-
% (w/w) % (w/w) % (w/w) for 0.5 mg for 5 mg for 25 mg Ingredient for capsule fill capsules capsules capsules Mono-fumarate of (R)-3-(6-(4- 0.46 4.65 23.23 methylphenyl)-pyridin-3-yloxy)-1-aza- bicyclo[2.2.2]octane Lactose monohydrate 65.24 61.05 42.47 Mcrocrystalline cellulose 25.00 25.00 25.00 Hypromellose 2.50 2.50 2.50 Sodium croscarmellose 6.00 6.00 6.00 Colloidal silicon dioxide 0.30 0.30 0.30 Magnesium stearate 0.50 0.50 0.50 Purified water* q.s. q.s. q.s. *removed during processing - Preparation process: Mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-lactose monohydrate, microcrystalline cellulose, a portion of sodium croscarmellose and hypromellose are dry mixed in a high shear mixer bowl, and granulating fluid (purified water) added. Once the granulation is complete, the wet granules are dried in a fluid bed drier and the dry granules are milled. The remaining sodium croscarmellose and colloidal silicon dioxide are passed through a suitable sieve and added to the dried granular material and blended in a suitable blending shell. This is achieved by co-sieving the sodium croscarmellose and the colloidal silicon dioxide with a portion of the milled granules through a suitable sieve into the blending shell. Similarly, the required amount of sieved magnesium stearate is added to the bulk granule and then mixed in the same blending shell. This final blend is encapsulated into capsules using automated equipment. Weigth ratio of capsule fill to empty capsule shells is 2:1.
- Film-coated tablets containing e.g. 0.5 mg of the mono-fumarate of (R)-3-(6-(4-may be prepared as follows:
- Weigh-in mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane (e.g. approx. 0.7%) and maize starch (e.g. approx. 13%), mix in a tumble blender (approx 100-300 rotations), pass through a sieve of approx. 0.25-1.0 mm mesh-size. Mix in a tumble blender (approx. 100-300 rotations).
- To above pre-mix add microcrystalline cellulose (e.g. approx. 25%), sprayed lactose (e.g. approx. 68%), sodium-carboxymethylcellulose XL (e.g. approx. 2%) and Aerosil (e.g. approx. 0.5%) and mix in a tumble blender (approx. 100-300 rotations). Pass this mixture through a sieve of approx. 0.5-1.0 mm mesh-size and mix again (approx. 100-300 rotations). Add the sodium-stearyl-fumarate (e.g. approx. 1.5%) through a handsieve at approx. 0.5-1.0 mm mesh-size and mix in a tumble blender (approx. 30-150 rotations).
- On a rotary press compress the above final blend to cores of approx. 100 mg, using the dosage specific tooling (e.g. approx. 6 mm, round, curved).
- Prepare a suspension in water with basic coating premixes black, red, yellow and/or white. Coat the above obtained cores in a perforated coating pan, and dry.
- Bilayer film-coated tablets containing e.g. 2.5 mg of the mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane may be prepared as follows:
- Weigh-in mono-fumarate of (R)-3-(6-(4-methylphenyI)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane coarse (e.g. approx. 15.5%), microcrystalline cellulose (e.g. approx. 25%), sprayed lactose (e.g. approx. 53%), sodium-carboxymethylcellulose XL (e.g. approx. 3%) and Aerosil (e.g. approx. 0.5%) and mix in a tumble blender (approx 100-300 rotations). Pass this mixture through a sieve of approx. 0.5-1.0 mm mesh-size and mix again (approx 100-300 rotations).
- Add the Na-stearyl-fumarate (e.g. approx. 3%) through a handsieve at approx. 0.5-10mm and mix in a tumble blender (approx 30-150 rotations).
- Weigh-in microcrystalline cellulose (e.g. approx. 26%), sprayed lactose (e.g. approx. 69%), sodium-carboxymethylcellulose XL (e.g. approx. 1.9%) and Aerosil (e.g. approx. 0.5%) and mix in a tumble blender (approx 100-300 rotations). Pass this mixture through a sieve of approx. 0.5-1.0 mm mesh-size and mix again (approx 100-300 rotations). Add the sodium-stearyl-fumarate (e.g. approx. 3%) through a handsieve at approx. 0.5-1.0 mm and mix in a tumble blender (approx 30-150 rotations).
- On a rotary press compress the above final blends to a bilayer tablet-core of approx. 100 mg with one placebo layer (approx. 77.5 mg) and one active layer (approx. 22.5 mg), using the dosage specific tooling (e.g. approx. 6 mm, round, curved).
- Prepare a suspension in water with basic coating premixes black, red, yellow and/or white. Coat the above obtained cores in a perforated coating pan, and dry.
- Film-coated tablets containing e.g. 50 mg of the mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane may be prepared as follows:
- Weigh-in mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane coarse (e.g. approx. 15.5%), microcrystalline cellulose (e.g. approx. 25%), sprayed lactose (e.g. approx. 53%), sodium-carboxymethylcellulose XL (e.g. approx. 3%) and Aerosil (e.g. approx. 0.5%) and mix in a tumble blender (approx. 100-300 rotations). Pass this mixture through a sieve of approx. 0.5-1.0 mm mesh-size and mix again (approx. 100-300 rotations).
- Add the sodium-stearyl-fumarate (e.g. approx. 3%) through a handsieve at approx. 0.5-10 mm and mix in a tumble blender (approx. 30-150 rotations).
- Compress the above final blend on a rotary press to cores, using the dosage specific tooling (e.g. approx. 15*5.9 mm, round, curved).
- Prepare a suspension in water with basic coating premixes black, red, yellow and/or white. Coat the above obtained cores in a perforated coating pan, and dry.
- The usefulness of the α7 nAChR agonists of the invention in the treatment of fatigue can be confirmed in a range of standard tests including those indicated below.
- Based on the activity/selectivity data shown below It is concluded that said compounds are selective agonists at the α7-nAChR,
- Assays: To assess α7-nAChR activity, a functional assay was employed using GH3 cells that recombinantly expressed human α7-nAChR. 40000 cells per well were seeded 48 h prior to the experiment on black 96-well plates (Costar) and incubated at 37° C. in a humidified atmosphere (5% CO2/95 air). On the day of the experiment, medium was removed by flicking the plates and replaced with 0.1 ml growth medium containing 0.002 mM Fluo-4, (Molecular Probes) in the presence of 2.5 mM probenecid (Sigma). The cells were incubated at 37° C. in a humidified atmosphere (5% CO2/95 air) for 1 h. Plates were flicked to remove excess of Fluo-4, washed twice with Hepes-buffered salt solution (HBSS, in mM: NaCl 130,
KCl 5,4,CaCl 2 2, MgSO4 0.8, NaH2PO4 0.9, glucose 25,Hepes 20, pH 7.4: HBS) and refilled with 0.1 ml of HBS containing antagonist when appropriate. The incubation in the presence of the antagonist lasted 3-5 minutes. Plates were placed in the cell plate stage of a FLIPR device (fluorimetric imaging plate reader, Molecular Devices, Sunnyvale, Calif., USA), After recording of the baseline (laser: excitation 488 nm at 1 W, COD camera opening of 0.4 seconds) the agonists (0.05 ml) were added to the cell plate using the FLIPR 96-tip pipettor while simultaneously recording the fluorescence, Calcium kinetic data were normalized to the maximal fitted response induced by epibatidine, which is a full agonist at α7-nAChR. Four parameter Hill equations were fitted to the concentration-response. Values of Emax (maximal effect in % compared to the epibatidine response) and EC50 (concentration producing half the maximal effect in μM) were derived from this fit. Assay described in: D Feuerbach et al, Neuropharmacology (2005), 48, 215-227. -
-
Compound B-1 Compound A-1 α7 EC50 (nM) ± SEM, n 39 ± 4.7, 18 100 ± 7.9, 17 α7 Emax ± SEM, n 73 ± 4.1%, 18 85 ± 5%, 17 α1β1γδ IC50 (nM) ± SEM, n 10715 ± 1376, 6 159222 ± 4306, 6 α4β2 IC50 (nM) ± SEM, n 3981 ± 770, 6 25119 ± 4794, 5 α3β4 IC50 (nM) ± SEM, n 5248 ± 609, 5 23097 ± 4123, 6 5-HT3 IC50 (nM) ± SEM, n 19054 ± 3811, 6 22324 ± 5869, 2 - Male transgenic mice with a knockout of the orexin peptide gene are used. Orexin-deficient mice express a phenotype with cataplexy events (observed as ‘behavioral arrests’) and a disrupted sleep pattern including fragmented sleep and sleepiness in their active period.
- The animals are observed and videotaped via infrared cameras during the first hours of the lights-off period which is the active phase of nocturnal rodents like mice. At this time, orexin-deficient mice show the most ‘behavioral arrests’. The number of these events can be furthermore increased by presenting a new environment. For this purpose, new saw dust, a running wheel, marbles and tunnels are placed in the test environment. The number of ‘behavioral arrests’ are offline counted by the experimenter for each hour of recording. Behavioral arrests were defined by phases of total inactivity outside the next box, which last longer than 10 second, preceded and followed by robust locomotor activity (see also Scammell et al., 2009, Sleep 32(1): 111-116). Some of the animals have temporal skull EEG electrodes implanted which are connected to transmitters. The EEG is recorded via a receiver and stored on a PC for further analysis. EEG is used to assess and to quantify sleep behavior and vigilance stage.
- A cross-over design is used because of the high inter- and intra-individual variability of the behaviors to be observed, Furthermore, to avoid habituation to the test environment, the animals are only tested once per week in the test environment. During the remaining days, the animals are in their homecage.
- For each experimental session, 3-4 mice are put into the
test environment 3 hours before lights-off. The first experimental session (week 1) is used to get a baseline (without treatment). The second and third sessions (weeks 2+3) are used for treatment (vehicle & compound, cross-over design, administration 5 minutes before lights-off). The fourth and last experimental session is again without treatment to evaluate a post-treatment baseline. -
FIG. 1 depicts the effects of 3 mg/kg compound B-4, orally administered directly before lights-off, on the number of narcoleptic episodes (behavioral arrests) in orexin-deficient mice. Compound B-4 decreased the number of narcoleptic episodes during the whole 4 hours observation period by ca. 25% (Paired t-test: t14=2.48, p=0.03;FIG. 1A +B). The reduction was more pronounced during the first hour (ca. 47%; t14=2.32, p=0.04;FIG. 1C ). -
FIG. 2 depicts the effects of 10 mg/kg compound B-1, orally administered directly before lights-off, on the number of narcoleptic episodes (behavioral arrests) in orexin-deficient mice. Compound B-1 significantly decreased the number of narcoleptic episodes during the first hour of the observation period by ca. 66% (p<0.05 Anova). - Animals have temporal skull EEG electrodes implanted which are connected to transmitters. Animals were group-housed (2 - 4) per cage at a constant temperature of 22±1° C., on a 12:12 light-dark schedule. The EEG is recorded via a receiver and stored on a PC for further analysis. EEG is used to assess and to quantify sleep behavior and vigilance stage.
- Animals were given a 1-day period of acclimatization in the recording cages with recording cables connected. On the 1st day of the experiment, EEG recordings were made continuously during a 22-hours period beginning at 11 A.M., 15 min after vehicle administration. On the second day of the experiment, EEG recordings were carried out in the same way, but 15 minutes after drug administration. In this way, each animal served as its own control, 10 animals were recorded from simultaneously in each experiment. Automatic evaluation of the nycthemeral cycle (REM sleep, classical sleep, wakefulness and an awake non-vigilant state termed “drowsiness”) was performed as described (Vigouret et al., 1978 Pharmacology 16 Suppl 1:156-73). In the present context, “quiet wake” and “active wake”, describe conscious animals in a resting and an active state, respectively, while “REM” and “NREM” represent sleep states,
-
FIG. 3 depicts the effects of 30 mg/kg compound B-1, orally administered 6 h after lights on (9:00) in mice (n=10) on quiet wake (a frequency, 9.5-12,5 Hz), active wake (13 frequency, 12.5-30.5 Hz; and y frequency, >30.5 Hz), REM sleep (8 frequency, 4,5-9,5 Hz) and NREM sleep (6 frequency, <4.5 Hz), Assessment period shown is 3 hours. Compound B-1 causes a decline of NREM sleep and increases the time spent in quiet wake. The numerical assessment ofFIG. 3 is given in table 1. -
TABLE 1 Mean difference drug-vehicle (min) assessed at time point 9:30 10:30 11:30 12:30 Quiet wake 14.3 6.1 −1.8 −0.9 (α frequency) Active wake 0.9 3.6 0.1 0.3 (β and γ frequencies) REM −2.2 −2.1 −0.9 −0.2 (θ frequency) NREM −12.4 −7.1 2.1 −0.1 (δ frequency) - Histamine (HA) is released all over the brain by tuberomammillary nucleus neurons, Evidence indicates that histaminergic neurons have a major role in wakefulness control. HA is metabolized by histamine-N-methyltransferase to tele-methylhistamine (tMHA) in some tissues, including brain.
- Mice (n=8) were treated during the first hour of the lights-on period and sacrificed 30 min later, Brain tissue was collected and subjected to LC-MS analysis (Croyal et al. Analytical Biochemistry, 2011, 409:28-36) to determine t-MHA levels.
-
FIG. 4 depicts the effects of different doses of compound B1 and A-1, orally administered to mice, 30 minutes after administration on brain tMHA levels. tMHA levels are significantly elevated for compound B-1 at all doses tested. For compound A-1 a significant elevation is seen for the 10 mg/kg dose. - Clinical testing of the α7 nAChA agonist of the invention may be conducted, for example, in one of the following study designs. The skilled physician may look at a number of aspects of patient behaviors and abilities, He will realize that such studies are considered as guidelines and the certain aspects of the studies may be modified and redefined depending on the circumstance and environment, for example.
- A patient population, with a normal control is dosed once a day for a week or longer tested. The test is designed to allow for improvement, i.e. that there is a measurable parameter increase of the impaired function. The patients are tested at the beginning and at the end of the dosage period and the results are compared and analyzed.
- A patient population with fatigue: e.g. fatigue associated with MS is dosed once a day for 12 weeks or longer and tested. The test is designed to allow for improvement, i.e. that there is a measurable parameter increase of the impaired domain. Examples of those tests include cognitive testing, the fatigue scale for motor and cognitive functions (FMC), Paced Auditory Serial Addition Test (PASAT), change in fatigue as measured on a visual analog scale (VAS), Fatigue Severity Scale (FSS) ,Neurological status as measured with the Expanded Disability Status Scale (EDSS) and Quality Of Life among others
- The patients are tested at the beginning and at the end of the dosage period and the results are compared and analyzed.
-
-
- When designing a trial, the skilled person will appreciate the need to protect both against floor and ceiling effects. In other words, the study design should allow the specific domain to be measurably raised or lowered.
- Conditions that artificially impair a function are one way to test enhancement of that function. Such conditions are, for example, sleep deprivation or pharmacological challenges.
- Placebo control is required for all trials.
-
FIG. 1 : Behavioral arrest, compound B-4 -
FIG. 2 : Behavioral arrest, compound B-1 -
FIG. 3 : EEG Measurements, compound B-1 -
FIG. 4 : Telemethyl histamine measurements, compounds B-1 and A-1 - A further aspect of the invention relates to a pharmaceutical composition comprising the α7 nAChR agonist of the invention for the treatment, amelioration, prevention or delay of progression of fatigue.
- A further aspect of the invention relates to a kit comprising an α7 nAChR agonist of the invention and instructions for using the agonist in the treatment, amelioration, prevention or delay of progression of fatigue in a subject in need of such treatment.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/700,469 US20220211679A1 (en) | 2013-01-15 | 2022-03-21 | Alpha 7 nicotinic acetylcholine receptor agonists |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361752772P | 2013-01-15 | 2013-01-15 | |
US201361752765P | 2013-01-15 | 2013-01-15 | |
PCT/IB2013/050368 WO2014111751A1 (en) | 2013-01-15 | 2013-01-15 | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy |
PCT/IB2014/058224 WO2014111837A1 (en) | 2013-01-15 | 2014-01-13 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
PCT/IB2014/058225 WO2014111838A1 (en) | 2013-01-15 | 2014-01-13 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US14/799,744 US20150313884A1 (en) | 2013-01-15 | 2015-07-15 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US15/686,919 US11311525B2 (en) | 2013-01-15 | 2017-08-25 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US17/700,469 US20220211679A1 (en) | 2013-01-15 | 2022-03-21 | Alpha 7 nicotinic acetylcholine receptor agonists |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/686,919 Continuation US11311525B2 (en) | 2013-01-15 | 2017-08-25 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220211679A1 true US20220211679A1 (en) | 2022-07-07 |
Family
ID=54354385
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/799,744 Abandoned US20150313884A1 (en) | 2013-01-15 | 2015-07-15 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US15/686,919 Active 2033-07-08 US11311525B2 (en) | 2013-01-15 | 2017-08-25 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US17/700,469 Pending US20220211679A1 (en) | 2013-01-15 | 2022-03-21 | Alpha 7 nicotinic acetylcholine receptor agonists |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/799,744 Abandoned US20150313884A1 (en) | 2013-01-15 | 2015-07-15 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
US15/686,919 Active 2033-07-08 US11311525B2 (en) | 2013-01-15 | 2017-08-25 | Use of alpha 7 nicotinic acetylcholine receptor agonists |
Country Status (1)
Country | Link |
---|---|
US (3) | US20150313884A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6263469B2 (en) * | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | Salt of azabicyclic di-aryl ether and method for producing the same or method for producing the precursor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132790A1 (en) * | 2002-09-25 | 2004-07-08 | Wenge Xie | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
US20070249617A1 (en) * | 2002-09-04 | 2007-10-25 | Dominik Feuerbach | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
AU2003250322B2 (en) | 2002-08-14 | 2010-01-21 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
AR049401A1 (en) | 2004-06-18 | 2006-07-26 | Novartis Ag | AZA-BICICLONONANS |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
WO2007093602A1 (en) | 2006-02-16 | 2007-08-23 | Neurosearch A/S | Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands |
CN100448468C (en) | 2006-11-14 | 2009-01-07 | 赵玉民 | Orally administered medicinal powder for treating gastric diseases |
SA08290475B1 (en) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof |
TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
WO2010056622A1 (en) | 2008-11-11 | 2010-05-20 | Targacept, Inc. | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
EP2959902A1 (en) | 2009-07-23 | 2015-12-30 | Novartis AG | Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia |
TWI558398B (en) | 2009-09-22 | 2016-11-21 | 諾華公司 | Use of nicotinic acetylcholine receptor alpha 7 activators |
WO2012031125A2 (en) * | 2010-09-01 | 2012-03-08 | The General Hospital Corporation | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine |
PL2637704T4 (en) | 2010-11-10 | 2015-08-31 | H Lundbeck As | Radiolabelled phenylimidazole-based ligands |
CA2825142A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
CA2840480A1 (en) | 2011-06-30 | 2013-01-03 | Toray Industries, Inc. | Antipruritic agent |
-
2015
- 2015-07-15 US US14/799,744 patent/US20150313884A1/en not_active Abandoned
-
2017
- 2017-08-25 US US15/686,919 patent/US11311525B2/en active Active
-
2022
- 2022-03-21 US US17/700,469 patent/US20220211679A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070249617A1 (en) * | 2002-09-04 | 2007-10-25 | Dominik Feuerbach | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
US20040132790A1 (en) * | 2002-09-25 | 2004-07-08 | Wenge Xie | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
Non-Patent Citations (3)
Title |
---|
Berge et al (Journal of Pharmaceutical Sciences, January 1977m volume 66, number 1, pages 1-19) (Year: 1977) * |
Breitbart et al., Arch Intern Med. 2001;161:411-420. (Year: 2001) * |
Sharpe et al (BMJ. 2002 Aug 31; 325(7362): 480–483). (Year: 2002) * |
Also Published As
Publication number | Publication date |
---|---|
US20170348294A1 (en) | 2017-12-07 |
US11311525B2 (en) | 2022-04-26 |
US20150313884A1 (en) | 2015-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11096916B2 (en) | Use of nicotinic acetylcholine receptor alpha 7 activators | |
AU2012210652B2 (en) | Use of nicotinic acetylcholine receptor alpha 7 activators | |
JP6657534B2 (en) | Use of alpha 7 nicotinic acetylcholine receptor agonist | |
JP2012523437A (en) | 5-HT4 receptor agonist compounds for the treatment of cognitive impairment | |
US20220211679A1 (en) | Alpha 7 nicotinic acetylcholine receptor agonists | |
CA2898043C (en) | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy | |
AU2012232711B2 (en) | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FENDT, MARKUS;FEUERBACH, DOMINIK;GOMEZ-MANCILLA, BALTAZAR;AND OTHERS;SIGNING DATES FROM 20150731 TO 20150811;REEL/FRAME:059442/0772 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC.;REEL/FRAME:059442/0711 Effective date: 20140117 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:059442/0685 Effective date: 20140327 Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JOHNS, DONALD;REEL/FRAME:059442/0670 Effective date: 20140113 Owner name: NOVARTIS PHARMA AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FENDT, MARKUS;FEUERBACH, DOMINIK;LOPEZ-LOPEZ, CRISTINA;AND OTHERS;SIGNING DATES FROM 20140116 TO 20140321;REEL/FRAME:059442/0628 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |